. 2022 Jul;23(6):684-692.

doi: 10.1111/hiv.13212. Epub 2021 Dec 9.

HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

Sarah Amele¹, Anastasia Karachalia Sandri², Alison Rodger¹, Linos Vandekerckhove³, Thomas Benfield⁴, Ana Milinkovic⁵, Claudine Duvivier⁶, Hans-Jürgen Stellbrink⁷, Helen Sambatakou⁸, Nikoloz Chkhartishvili⁹, Luis Caldeira¹⁰, Monserrat Laguno¹¹, Pere Domingo¹², Gilles Wandeler¹³, Martin Gisinger¹⁴, Elena Kuzovatova¹⁵, Gordana Dragovic¹⁶, Brygida Knysz¹⁷, Raimonda Matulionyte¹⁸, Jürgen Kurt Rockstroh¹⁹, Jens Dilling Lundgren², Amanda Mocroft^{1

2}, Lars Peters²; EuroSIDA study group

Collaborators, Affiliations

Collaborators

EuroSIDA study group:
A Harxhi, M Losso, M Kundro, B Schmied, R Zangerle, I Karpov, A Vassilenko, V M Mitsura, D Paduto, N Clumeck, S De Wit, M Delforge, E Florence, L Vandekerckhove, V Hadziosmanovic, J Begovac, L Machala, D Jilich, D Sedlacek, G Kronborg, T Benfield, J Gerstoft, T Katzenstein, C Pedersen, I S Johansen, L Ostergaard, L Wiese, N F Moller, L N Nielsen, K Zilmer, Jelena Smidt, I Aho, J-P Viard, P-M Girard, C Pradier, E Fontas, C Duvivier, J Rockstroh, G Behrens, O Degen, H J Stellbrink, C Stefan, J Bogner, G Fätkenheuer, N Chkhartishvili, H Sambatakou, G Adamis, N Paissios, J Szlávik, M Gottfredsson, E Devitt, L Tau, D Turner, M Burke, E Shahar, G Hassoun, H Elinav, M Haouzi, D Elbirt, A D'Arminio Monforte, R Esposito, I Mazeu, C Mussini, F Mazzotta, A Gabbuti, A Lazzarin, A Castagna, N Gianotti, M Galli, A Ridolfo, L Sacco, V Uzdaviniene, R Matulionyte, T Staub, R Hemmer, S Dragas, M Stevanovic, P Reiss, J Trajanovska, D H Reikvam, A Maeland, J Bruun, B Knysz, J Gasiorowski, M Inglot, E Bakowska, R Flisiak, A Grzeszczuk, M Parczewski, K Maciejewska, B Aksak-Was, M Beniowski, E Mularska, E Jablonowska, J Kamerys, K Wojcik, I Mozer-Lisewska, B Rozplochowski, A Zagalo, K Mansinho, F Maltez, R Radoi, C Oprea, Carol Davila, A Yakovlev, T Trofimora, I Khromova, E Kuzovatova, I N Blokhina, Nizhny Novogrod, E Borodulina, E Vdoushkina, J Ranin, J Tomazic, J M Miro, J M Miró, E Martinez, F Garcia, J L Blanco, M Martinez-Rebollar, J Mallolas, P Callau, J Rojas, A Inciarta, S Moreno, S Del Campo, B Clotet, A Jou, R Paredes, J Puig, J M Llibre, J R Santos, P Domingo, M Gutierrez, G Mateo, M A Sambeat, J M Laporte, K Falconer, A Thalme, A Sonnerborg, J Brannstrom, L Flamholc, A Scherrer, R Weber, M Cavassini, A Calmy, H Furrer, M Battegay, P Schmid, A Kuznetsova, J Mikhalik, M Sluzhynska, A Milinkovic, A M Johnson, E Simons, S Edwards, A Phillips, M A Johnson, A Mocroft, C Orkin, A Winston, A Clarke, C Leen, I Karpov, M Losso, J Lundgren, J Rockstroh, I Aho, L D Rasmussen, V Svedhem, G Wandeler, C Pradier, N Chkhartishvili, R Matulionyte, C Oprea, J D Kowalska, J Begovac, J M Miró, G Guaraldi, R Paredes, G Wandeler, R Paredes, L Peters, O Kirk, L Peters, A Bojesen, D Raben, E V Hansen, D Kristensen, J F Larsen, A H Fischer, A Mocroft, A Phillips, A Cozzi-Lepri, S Amele, A Pelchen-Matthews, A Roen, E Tusch, W Bannister, J Reekie

Affiliations

¹ Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, UK.
² CHIP, Rigshospitalet, Copenhagen, Denmark.
³ Ghent University Hospital, Ghent, Belgium.
⁴ Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
⁵ Chelsea and Westminster Hospital, London, UK.
⁶ AP-HP - Necker Enfants Malades Hospital, Infectious Diseases Department; Necker Pasteur Center for Infectious Diseases and Tropical Medicine; Université de Paris; IHU Imagine, Paris, France.
⁷ ICH Study Center, Hamburg, Germany.
⁸ Ippokration General Hospital, Athens, Greece.
⁹ Infectious Diseases, AIDS & Clinical Immunology Research Center, Tbilisi, Georgia.
¹⁰ Santa Maria University Hospital, University of Lisbon, Lisbon, Portugal.
¹¹ Infectious Diseases Service, Hospital Clinic, Barcelona, Spain.
¹² Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
¹³ Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
¹⁴ Medical University of Innsbruck, Innsbruck, Austria.
¹⁵ Nizhny Novgorod Scientific and Research Institute, Nizhny Novgorod, Russia.
¹⁶ Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade, Belgrade, Serbia.
¹⁷ Wroclaw Medical University, Wroclaw, Poland.
¹⁸ Department of Infectious Diseases and Dermatovenerology, Faculty of Medicine, Vilnius University; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
¹⁹ Universitäts Klinik Bonn, Bonn, Germany.

PMID: 34882940
DOI: 10.1111/hiv.13212

Free article

HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

Sarah Amele et al. HIV Med. 2022 Jul.

Free article

. 2022 Jul;23(6):684-692.

doi: 10.1111/hiv.13212. Epub 2021 Dec 9.

Authors

Collaborators

EuroSIDA study group:
A Harxhi, M Losso, M Kundro, B Schmied, R Zangerle, I Karpov, A Vassilenko, V M Mitsura, D Paduto, N Clumeck, S De Wit, M Delforge, E Florence, L Vandekerckhove, V Hadziosmanovic, J Begovac, L Machala, D Jilich, D Sedlacek, G Kronborg, T Benfield, J Gerstoft, T Katzenstein, C Pedersen, I S Johansen, L Ostergaard, L Wiese, N F Moller, L N Nielsen, K Zilmer, Jelena Smidt, I Aho, J-P Viard, P-M Girard, C Pradier, E Fontas, C Duvivier, J Rockstroh, G Behrens, O Degen, H J Stellbrink, C Stefan, J Bogner, G Fätkenheuer, N Chkhartishvili, H Sambatakou, G Adamis, N Paissios, J Szlávik, M Gottfredsson, E Devitt, L Tau, D Turner, M Burke, E Shahar, G Hassoun, H Elinav, M Haouzi, D Elbirt, A D'Arminio Monforte, R Esposito, I Mazeu, C Mussini, F Mazzotta, A Gabbuti, A Lazzarin, A Castagna, N Gianotti, M Galli, A Ridolfo, L Sacco, V Uzdaviniene, R Matulionyte, T Staub, R Hemmer, S Dragas, M Stevanovic, P Reiss, J Trajanovska, D H Reikvam, A Maeland, J Bruun, B Knysz, J Gasiorowski, M Inglot, E Bakowska, R Flisiak, A Grzeszczuk, M Parczewski, K Maciejewska, B Aksak-Was, M Beniowski, E Mularska, E Jablonowska, J Kamerys, K Wojcik, I Mozer-Lisewska, B Rozplochowski, A Zagalo, K Mansinho, F Maltez, R Radoi, C Oprea, Carol Davila, A Yakovlev, T Trofimora, I Khromova, E Kuzovatova, I N Blokhina, Nizhny Novogrod, E Borodulina, E Vdoushkina, J Ranin, J Tomazic, J M Miro, J M Miró, E Martinez, F Garcia, J L Blanco, M Martinez-Rebollar, J Mallolas, P Callau, J Rojas, A Inciarta, S Moreno, S Del Campo, B Clotet, A Jou, R Paredes, J Puig, J M Llibre, J R Santos, P Domingo, M Gutierrez, G Mateo, M A Sambeat, J M Laporte, K Falconer, A Thalme, A Sonnerborg, J Brannstrom, L Flamholc, A Scherrer, R Weber, M Cavassini, A Calmy, H Furrer, M Battegay, P Schmid, A Kuznetsova, J Mikhalik, M Sluzhynska, A Milinkovic, A M Johnson, E Simons, S Edwards, A Phillips, M A Johnson, A Mocroft, C Orkin, A Winston, A Clarke, C Leen, I Karpov, M Losso, J Lundgren, J Rockstroh, I Aho, L D Rasmussen, V Svedhem, G Wandeler, C Pradier, N Chkhartishvili, R Matulionyte, C Oprea, J D Kowalska, J Begovac, J M Miró, G Guaraldi, R Paredes, G Wandeler, R Paredes, L Peters, O Kirk, L Peters, A Bojesen, D Raben, E V Hansen, D Kristensen, J F Larsen, A H Fischer, A Mocroft, A Phillips, A Cozzi-Lepri, S Amele, A Pelchen-Matthews, A Roen, E Tusch, W Bannister, J Reekie

Affiliations

¹ Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, UK.
² CHIP, Rigshospitalet, Copenhagen, Denmark.
³ Ghent University Hospital, Ghent, Belgium.
⁴ Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
⁵ Chelsea and Westminster Hospital, London, UK.
⁶ AP-HP - Necker Enfants Malades Hospital, Infectious Diseases Department; Necker Pasteur Center for Infectious Diseases and Tropical Medicine; Université de Paris; IHU Imagine, Paris, France.
⁷ ICH Study Center, Hamburg, Germany.
⁸ Ippokration General Hospital, Athens, Greece.
⁹ Infectious Diseases, AIDS & Clinical Immunology Research Center, Tbilisi, Georgia.
¹⁰ Santa Maria University Hospital, University of Lisbon, Lisbon, Portugal.
¹¹ Infectious Diseases Service, Hospital Clinic, Barcelona, Spain.
¹² Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
¹³ Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
¹⁴ Medical University of Innsbruck, Innsbruck, Austria.
¹⁵ Nizhny Novgorod Scientific and Research Institute, Nizhny Novgorod, Russia.
¹⁶ Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade, Belgrade, Serbia.
¹⁷ Wroclaw Medical University, Wroclaw, Poland.
¹⁸ Department of Infectious Diseases and Dermatovenerology, Faculty of Medicine, Vilnius University; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
¹⁹ Universitäts Klinik Bonn, Bonn, Germany.

PMID: 34882940
DOI: 10.1111/hiv.13212

Abstract

Objectives: Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected individuals, high rates of reinfection may hamper efforts to eliminate HCV in this population. We investigated reinfection after sustained virological response (SVR) in HIV/HCV-coinfected individuals in Europe.

Methods: Factors associated with odds of reinfection by 2 years after SVR in EuroSIDA participants with one or more HCV-RNA test and 2 years follow-up were assessed using logistic regression.

Results: Overall, 1022 individuals were included. The median age was 50 (interquartile range: 43-54 years), and most were male (78%), injection drug users (52%), and received interferon (IFN)-free DAAs (62%). By 24 months, 75 [7.3%, 95% confidence interval (CI): 5.7-8.9%] individuals were reinfected. Among individuals treated prior to 2014, 16.1% were reinfected compared with 4.2% and 8.3%, respectively, among those treated during or after 2014 with IFN-free and IFN-based therapy. After adjustment, individuals who had started treatment during or after 2014 with IFN-free or IFN-based therapy had significantly lower odds of reinfection (adjusted odds ratio = 0.21, 95% CI: 0.11-0.38; 0.43, 95% CI: 0.22-0.83) compared with those who had received therapy before 2014. There were no significant differences in odds of reinfection according to age, gender, European region, HIV transmission risk group or liver fibrosis.

Conclusions: Among HIV/HCV-coinfected individuals in Europe, 7.3% were reinfected with HCV within 24 months of achieving SVR, with evidence suggesting that this is decreasing over time and with use of newer HCV regimens. Harm reduction to reduce reinfection and surveillance to detect early reinfection with an offer of treatment are essential to eliminate HCV.

Keywords: HCV; HIV; direct-acting antivirals; interferon; reinfection.

PubMed Disclaimer

References

REFERENCES

1. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898.
1. Accessed July 2, 2021. https://apps.who.int/iris/bitstream/handle/10665/206453/WHO_HIV_2016.04_.... In: 2021.
1. Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61(5):730-740.
1. Ingiliz P, Wehmeyer MH, Boesecke C, et al. Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: current incidence rates, compared with rates during the interferon era. Clin Infect Dis. 2020;71(5):1248-1254.
1. Berenguer J, Gil-Martin A, Jarrin I, et al. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals. AIDS. 2019;33(4):685-689.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

Collaborators

Affiliations

HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

Authors

Collaborators

Affiliations

Abstract

References

REFERENCES

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical